BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbed organ doses in (177)Lu-DOTATATE therapy, three methods based on activity concentrations are currently in use: the small volume of interest (sVOI) method, and two methods based on large VOIs either on anatomical CT (aVOI) or on thresholds on functional images (tVOI). The main aim of the present work was to validate the sVOI in comparison to the other two methods regarding agreement and time efficiency. Secondary aims were to investigate inter-observer variability for the sVOI and the change of functional organ volumes following therapy. METHODS: Thirty patients diagnosed with neuroendocrine tumours undergoing therapy with (177)Lu-DOTATATE we...
Recently, there has been a growth in using post-treatment dosimetry after the first treatment cycle ...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...
BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbe...
BACKGROUND: Lu-177-(DOTAO,Tyr3) octreotate is a new treatment modality for disseminated neuroendocri...
Objective(s): To investigate and compare quantitative accuracy of kidney absorbed dose measures made...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
International audienceAim/Introduction: Patients with unresectable neuroendocrine tumors can be trea...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Abstract Background This study aims to assess both feasibility and accuracy of renal dosimetry imagi...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Purpose Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingl...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Recently, there has been a growth in using post-treatment dosimetry after the first treatment cycle ...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...
BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbe...
BACKGROUND: Lu-177-(DOTAO,Tyr3) octreotate is a new treatment modality for disseminated neuroendocri...
Objective(s): To investigate and compare quantitative accuracy of kidney absorbed dose measures made...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
International audienceAim/Introduction: Patients with unresectable neuroendocrine tumors can be trea...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Abstract Background This study aims to assess both feasibility and accuracy of renal dosimetry imagi...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Purpose Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingl...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Recently, there has been a growth in using post-treatment dosimetry after the first treatment cycle ...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...